Chengdu Shengnuo Biotechnology Co., Ltd.

Primary objective: To evaluate the bioequivalence of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. with the reference preparation, using AstraZeneca AB's exenatide injection, which is marketed in China, as the reference preparation; Secondary objective: To evaluate the safety of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. and the effect of anti-drug antibodies on the pharmacokinetics of exenatide.

Primary objectives: To evaluate the safety and tolerability of single and multiple injections of RAB001 at different doses. Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of single and multiple injections of RAB001 at different doses; (2) To evaluate the pharmacodynamic characteristics of single and multiple injections of RAB001 at different doses; (3) To evaluate the immunogenicity of single and multiple injections of RAB001 at different doses.

Liraglutide injection (specification: 3mL:18mg) developed by Chengdu Shengnuo Biopharmaceutical Co., Ltd. was used as the test preparation (T), and liraglutide injection (trade name: Novoligy®, specification: 3mL:18mg) produced by Novo Nordisk (China) Pharmaceuticals Co., Ltd. was used as the reference preparation (R). The pharmacokinetic parameters of the test preparation and the reference preparation were studied when administered as a single dose in healthy volunteers under fasting state, and the human bioequivalence of the two preparations was preliminarily evaluated.